Cargando…
KIT and PDGFRA Variants and the Survival of Patients with Gastrointestinal Stromal Tumor Treated with Adjuvant Imatinib
SIMPLE SUMMARY: Gastrointestinal stromal tumor (GIST) is the most common type of sarcoma that arises from the gastrointestinal tract, most frequently from the stomach. The malignancy potential of GISTs varies greatly; some are aggressive cancers. Most localized GISTs are cured with surgery. Recent r...
Autor principal: | Joensuu, Heikki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10417000/ https://www.ncbi.nlm.nih.gov/pubmed/37568695 http://dx.doi.org/10.3390/cancers15153879 |
Ejemplares similares
-
KIT and PDGFRA Mutations and Survival of Gastrointestinal Stromal Tumor Patients Treated with Adjuvant Imatinib in a Randomized Trial
por: Joensuu, Heikki, et al.
Publicado: (2023) -
Impact of the KIT/PDGFRA genotype on prognosis in imatinib‐naïve Japanese patients with gastrointestinal stromal tumor
por: Cho, Haruhiko, et al.
Publicado: (2021) -
Intratumoral KIT mutational heterogeneity and recurrent KIT/ PDGFRA mutations in KIT/PDGFRA wild-type gastrointestinal stromal tumors
por: Gao, Jing, et al.
Publicado: (2016) -
Risk factors for gastrointestinal stromal tumor recurrence in patients treated with adjuvant imatinib
por: Joensuu, Heikki, et al.
Publicado: (2014) -
KIT and PDGFRa mutational patterns in Sardinian patients with gastrointestinal stromal tumors
por: Palomba, Grazia, et al.
Publicado: (2020)